Welcome to the February edition of the Burjeel Holdings Feat Focus Newsletter. This has been a month of significant achievements. This month, we expanded our extensive cancer care network to Al Ain and signed an MoU with the Egyptian Health Ministry to establish a world-class Bone Marrow Transplant program.

We acquired an 80% equity stake in the Dubai-based Advanced Care Oncology Center (ACOC). Across the GCC, we will launch ACOC-branded radiation oncology stand-alone centers to meet the growing cancer care needs in the region. Besides, we secured AED 225 million-worth operations and management contracts to boost our efforts to contribute to the UAE’s healthcare vision.

Under the guidance of DoH, our experts at BMC marked a significant healthcare milestone by administering Givosiran, an innovative treatment, for the first time in the UAE to treat a rare genetic disorder. Our Orthopedic and Hematology-Oncology programs received the coveted NIHS accreditation, underlining our excellence in medical education and training.

Be a part of our journey as we set new standards in healthcare, transforming many lives.

Read the newsletterhere.

Burjeel's Healthcare Excellence in February